Date published: 2025-10-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olfr317 Activators

Chemical activators of Olfr317 can be understood as a diverse group of molecules that share the ability to bind to and initiate a signaling cascade through this specific olfactory receptor. Among these activators, acetophenone, benzaldehyde, and cinnamaldehyde interact with Olfr317 by fitting snugly into its odorant-binding site, which is a specialized pocket designed to accommodate aromatic or volatile compounds. This interaction causes the receptor to change its shape, a process known as a conformational change. This structural rearrangement is not merely a physical alteration but the critical first step in the signaling process, as it enables the subsequent activation of associated G protein-coupled receptor (GPCR) pathways. Following this, a series of intracellular events unfold, which translate the chemical binding into an electrical signal, ultimately perceived as an odor.

Furthermore, molecules like ethyl vanillin, eugenol, and isoeugenol, despite their structural differences, also activate Olfr317 by binding to its ligand-binding domain. This triggers similar conformational changes, underscoring the versatility of the receptor to accommodate various substances and yet initiate a comparable end response. Other activators such as limonene, methyl salicylate, and phenethyl alcohol further illustrate the receptor's broad ligand specificity. Additionally, vanillin, along with alpha-ionone and beta-ionone, engage with Olfr317 in a like manner. These interactions highlight the dynamic nature of the receptor, which is capable of binding to different chemical structures and, through a common mechanism involving conformational changes and the activation of GPCR signaling, ultimately contribute to the perception of a wide range of odors.

SEE ALSO...

Items 11 to 11 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

beta-Ionone

14901-07-6sc-291976
25 ml
$83.00
(0)

Beta-ionone can activate Olfr317 by binding to the receptor's ligand-binding domain, which induces a conformational change, triggering the G protein-coupled receptor signaling cascade and resulting in the receptor's activation.